X-RAY psoralen activated cancer therapy (X-PACT) with associated treatments

Patent metadata

Field	Value
Publication number	US-11207409-B2
Application number	US-201815992852-A
Country	US
Kind code	B2
Filing date	May 30, 2018
Priority date	May 31, 2017
Publication date	Dec 28, 2021
Grant date	Dec 28, 2021

Abstract

A system (and associated method) for treating a human or animal body. The system has a photoactivatable drug for treating a first diseased site, a first pharmaceutically acceptable carrier including one or more phosphorescent or fluorescent agents which are capable of emitting an activation energy into the body which activates the photoactivatable drug, a first device which infuses the first diseased site with a photoactivatable drug and the first pharmaceutically acceptable carrier, a first energy source which irradiates the diseased site with an initiation energy to thereby initiate emission of the activation energy into the body, and a supplemental treatment device which administers one or both of a therapeutic drug or radiation to the body at a second diseased site or the first diseased site, to provide an immune system stimulation in the body.

First claim

The invention claimed is:

1. A method for treating a first diseased site in a human or animal body, comprising:
infusing the first diseased site with a photoactivatable drug;
generating an activation energy in situ in the human or animal body sufficient to activate the photoactivatable drug, thereby activating the photoactivatable drug, wherein said activating the photoactivatable drug causes an auto-vaccine effect in the human or animal body;
administering a supplemental treatment to a second diseased site or elsewhere in the body other than the first diseased site, and
directing radiation to a location elsewhere in the body different from the first and second diseased sites.

2. The method of claim 1 , wherein generating the activation energy in situ in the human or animal body comprises injecting in the first diseased site a pharmaceutical carrier including one or more phosphorescent or fluorescent agents which are capable of emitting an activation energy in the human or animal body for activating the photoactivatable drug;
applying an initiation energy to the first diseased site, whereby the initiation energy is absorbed by the one or more phosphorescent or fluorescent agents, which emit the activation energy inside the first diseased site.

3. The method of claim 2 , wherein applying an initiation energy comprises providing a controlled radiation dose of x-ray or high energy electrons to the first or second diseased site.

4. The method of claim 2 , wherein applying an initiation energy comprises providing a controlled radiation dose of x-ray or high energy electrons to a tumor at at least one of the first or second diseased sites.

5. The method of claim 4 , further comprising providing a booster treatment to a tumor at at least one of the first or second diseased sites, said booster treatment repeated on a periodic basis after an initial treatment of the tumor.

6. The method of claim 2 , further comprising radiating the human or animal body with the first energy source or as part of the supplemental treatment at least one of a palliative level, a therapeutic level, or a radiation induced cell kill level.

7. The method of claim 6 , wherein said radiating the human or animal body comprises radiating at said palliative level.

8. The method of claim 6 , wherein said radiating the human or animal body comprises radiating at said radiation induced cell kill level.

9. The method of claim 6 , wherein said radiating the human or animal body comprises radiating at said palliative level as an intervening treatment after an initial treatment with said one or more phosphorescent or fluorescent agents, said photoactivatable drug, and said applying initiation energy to the first diseased site and prior to a subsequent booster treatment with said phosphors, said photoactivatable drug, and said applying initiation energy to the first diseased site.

10. The method of claim 1 , further comprising providing a booster treatment to the diseased site, before, during and/or after an initial treatment of the first or second diseased site.

11. The method of claim 10 , wherein said booster treatment is performed before an initial treatment of the first or second diseased site.

12. The method of claim 10 , wherein said booster treatment is performed during an initial treatment of the first or second diseased site.

13. The method of claim 10 , wherein said booster treatment is performed after an initial treatment of the first or second diseased site.

14. The method of claim 13 , wherein said booster treatment is repeated on a periodic basis after an initial treatment of the first or second diseased site.

15. The method of claim 10 , wherein, in the booster treatment, at least one of concentration of the phosphorescent or fluorescent agents, photoactivatable drug concentration, or the radiation dose is increased by a factor of at least two times, five times, or ten times respective initial values.

16. The method of claim 10 , wherein the booster treatment produces psoralen-modified cancer cells or X-ray modified cancer cells.

17. The method of claim 10 , wherein the booster treatment produces radiation damaged cancer cells.

18. The method of claim 10 , further comprising delaying a period between booster treatments according to a tolerance level of the human or animal body for radiation-modified cells generated during the booster treatment.

19. The method of claim 10 , wherein the booster treatment provides radiating the human or animal body at either a palliative level or a therapeutic level.

20. The method of claim 19 , wherein the radiating the human or animal body at either a palliative or therapeutic level comprises radiating the first or second diseased site before, during, and/or after an initial treatment with said one or more phosphorescent or fluorescent agents, said photoactivatable drug, and said applying an initiation energy to the first diseased site.

21. The method of claim 1 , further comprising stunting growth of a tumor in the human or animal body until the activated photoactivatable drug causes said auto-vaccine effect in the human or animal body.

22. The method of claim 1 , further comprising stimulating said auto-vaccine effect in the human or animal body.

23. The method of claim 22 , wherein stimulating said auto-vaccine effect comprises injecting a vaccine into the human or animal body.

24. The method of claim 23 , wherein stimulating said auto-vaccine effect comprises injecting a tetanus vaccine into the human or animal body.

25. The method of claim 22 , further comprising radiating the human or animal body with a palliative level of radiation.

26. The method of claim 1 , providing a therapeutic drug as an immune system stimulant.

27. The method of claim 26 , wherein the therapeutic drug comprises a vaccine.

28. The method of claim 1 , providing a therapeutic drug as the supplemental treatment.

29. The method of claim 28 , wherein the therapeutic drug comprises a chemotherapy drug.

30. The method of claim 1 , providing for the supplemental treatment a therapeutic drug comprising at least one of a vaccine or a chemotherapy drug applied to the second diseased site or elsewhere in the body.

31. The method of claim 1 , providing for the supplemental treatment a therapeutic drug comprising a tetanus vaccine applied to the second diseased site or elsewhere in the body.

32. The method of claim 1 , providing for the supplemental treatment a therapeutic drug comprising at least one of an immunotherapy drug, a cancer vaccine, an adjuvant, a cytokine, a monoclonal antibody, or a genetically engineered T cell applied to the second diseased site or elsewhere in the body.

Assignees

• Immunolight Llc
• Univ Duke

Inventors

• Bourke Jr Frederic A
• Dewhirst Mark
• Spector Neil
• Yoon Paul
• Adamson Justus
• Alcorta David
• Lyerly Kim
• Liu Leihua
• Osada Takuya
• Oldham Mark
• Fathi Zakaryae
• Beyer Wayne F
• Walder Harold

Classifications

• A61K31/37 Primary

  Coumarins, e.g. psoralen · CPC title

• A61N2005/0661

  ultraviolet · CPC title

• A61N5/062

  Photodynamic therapy, i.e. excitation of an agent · CPC title

• A61K41/0066

  Psoralene-activated UV-A photochemotherapy (PUVA-therapy), e.g. for treatment of psoriasis or eczema, extracorporeal photopheresis with psoralens or fucocoumarins · CPC title

• A61K31/409

  having four such rings, e.g. porphine derivatives, bilirubin, biliverdine (hemin, hematin A61K31/555) · CPC title